|
1
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Simard EP, Dorell C, et al:
Annual report to the nation on the status of cancer, 1975–2009,
featuring the burden and trends in human papillomavirus
(HPV)-associated cancers and HPV vaccination coverage levels. J
Natl Cancer Inst. 105:175–201. 2013.
|
|
3
|
Gazdar AF: The molecular and cellular
basis of human lung cancer. Anticancer Res. 14:261–267.
1994.PubMed/NCBI
|
|
4
|
Graziano SL, Gamble GP, Newman NB, et al:
Prognostic significance of K-ras codon 12 mutations in
patients with resected stage I and II non-small-cell lung cancer. J
Clin Oncol. 17:668–675. 1999.
|
|
5
|
Ding L, Getz G, Wheeler DA, et al: Somatic
mutations affect key pathways in lung adenocarcinoma. Nature.
455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weir BA, Woo MS, Getz G, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mitsudomi T and Yatabe Y: Epidermal growth
factor receptor in relation to tumor development: EGFR gene and
cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
DeBerardinis RJ, Lum JJ, Hatzivassiliou G
and Thompson CB: The biology of cancer: metabolic reprogramming
fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones RG and Thompson CB: Tumor
suppressors and cell metabolism: a recipe for cancer growth. Genes
Dev. 23:537–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kroemer G, Galluzzi L and Brenner C:
Mitochondrial membrane permeabilization in cell death. Physiol Rev.
87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fulda S, Galluzzi L and Kroemer G:
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov.
9:447–464. 2010. View
Article : Google Scholar
|
|
14
|
Mathupala SP, Ko YH and Pedersen PL: The
pivotal roles of mitochondria in cancer: Warburg and beyond and
encouraging prospects for effective therapies. Biochim Biophys
Acta. 1797:1225–1230. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haigis MC and Guarente LP: Mammalian
sirtuins - emerging roles in physiology, aging, and calorie
restriction. Genes Dev. 20:2913–2921. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Milne JC and Denu JM: The Sirtuin family:
therapeutic targets to treat diseases of aging. Curr Opin Chem
Biol. 12:11–17. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lombard DB, Alt FW, Cheng HL, et al:
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine
acetylation. Mol Cell Biol. 27:8807–8814. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashraf N, Zino S, Macintyre A, et al:
Altered sirtuin expression is associated with node-positive breast
cancer. Br J Cancer. 95:1056–1061. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HS, Patel K, Muldoon-Jacobs K, et al:
SIRT3 is a mitochondria-localized tumor suppressor required for
maintenance of mitochondrial integrity and metabolism during
stress. Cancer Cell. 17:41–52. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Finley LW, Carracedo A, Lee J, et al:
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α
destabilization. Cancer Cell. 19:416–428. 2011.PubMed/NCBI
|
|
21
|
Zhang YY and Zhou LM: Sirt3 inhibits
hepatocellular carcinoma cell growth through reducing Mdm2-mediated
p53 degradation. Biochem Biophys Res Commun. 423:26–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang P, Xu TY, Guan YF, Su DF, Fan GR and
Miao CY: Perivascular adipose tissue-derived visfatin is a vascular
smooth muscle cell growth factor: role of nicotinamide
mononucleotide. Cardiovasc Res. 81:370–380. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang P, Xu TY, Guan YF, et al:
Nicotinamide phosphoribosyltransferase protects against ischemic
stroke through SIRT1-dependent adenosine monophosphate-activated
kinase pathway. Ann Neurol. 69:360–374. 2011. View Article : Google Scholar
|
|
24
|
Wang P, Zhang RY, Song J, et al: Loss of
AMP-activated protein kinase-α2 impairs the insulin-sensitizing
effect of calorie restriction in skeletal muscle. Diabetes.
61:1051–1061. 2012.
|
|
25
|
Wang P, Guan YF, Du H, Zhai QW, Su DF and
Miao CY: Induction of autophagy contributes to the neuroprotection
of nicotinamide phosphoribosyltransferase in cerebral ischemia.
Autophagy. 8:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim SC, Sprung R, Chen Y, et al: Substrate
and functional diversity of lysine acetylation revealed by a
proteomics survey. Mol Cell. 23:607–618. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi T, Wang F, Stieren E and Tong Q:
SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial
function and thermogenesis in brown adipocytes. J Biol Chem.
280:13560–13567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arif M, Senapati P, Shandilya J and Kundu
TK: Protein lysine acetylation in cellular function and its role in
cancer manifestation. Biochim Biophys Acta. 1799:702–716. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Benhar M, Engelberg D and Levitzki A: ROS,
stress-activated kinases and stress signaling in cancer. EMBO Rep.
3:420–425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chin SF, Teschendorff AE, Marioni JC, et
al: High-resolution aCGH and expression profiling identifies a
novel genomic subtype of ER negative breast cancer. Genome Biol.
8:R2152007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang CZ, Liu L, Cai M, et al: Low SIRT3
expression correlates with poor differentiation and unfavorable
prognosis in primary hepatocellular carcinoma. PLoS One.
7:e517032012. View Article : Google Scholar
|
|
32
|
Bell EL, Emerling BM, Ricoult SJ and
Guarente L: SirT3 suppresses hypoxia inducible factor 1α and tumor
growth by inhibiting mitochondrial ROS production. Oncogene.
30:2986–2996. 2011.PubMed/NCBI
|
|
33
|
Alhazzazi TY, Kamarajan P, Joo N, et al:
Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral
cancer. Cancer. 117:1670–1678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Susin SA, Lorenzo HK, Zamzami N, et al:
Molecular characterization of mitochondrial apoptosis-inducing
factor. Nature. 397:441–446. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Langley E, Pearson M, Faretta M, et al:
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced
cellular senescence. EMBO J. 21:2383–2396. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng HL, Mostoslavsky R, Saito S, et al:
Developmental defects and p53 hyperacetylation in Sir2 homolog
(SIRT1)-deficient mice. Proc Natl Acad Sci USA. 100:10794–10799.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Greenblatt MS, Bennett WP, Hollstein M and
Harris CC: Mutations in the p53 tumor suppressor gene: clues to
cancer etiology and molecular pathogenesis. Cancer Res.
54:4855–4878. 1994.PubMed/NCBI
|
